- Home
- PLXS vs OGN Comparison
PLXS vs OGN Comparison
Compare PLXS & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLXS
- OGN
- Stock Information
- Founded
- PLXS 1979
- OGN 1923
- Country
- PLXS United States
- OGN United States
- Employees
- PLXS N/A
- OGN N/A
- Industry
- PLXS Electrical Products
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- PLXS Technology
- OGN Health Care
- Exchange
- PLXS Nasdaq
- OGN Nasdaq
- Market Cap
- PLXS 4.5B
- OGN 3.9B
- IPO Year
- PLXS 1986
- OGN N/A
- Fundamental
- Price
- PLXS $159.87
- OGN $14.50
- Analyst Decision
- PLXS Buy
- OGN Hold
- Analyst Count
- PLXS 5
- OGN 3
- Target Price
- PLXS $147.25
- OGN $21.33
- AVG Volume (30 Days)
- PLXS 247.3K
- OGN 4.5M
- Earning Date
- PLXS 01-22-2025
- OGN 02-13-2025
- Dividend Yield
- PLXS N/A
- OGN 7.68%
- EPS Growth
- PLXS N/A
- OGN 120.97
- EPS
- PLXS 4.01
- OGN 5.04
- Revenue
- PLXS $3,960,827,000.00
- OGN $6,409,000,000.00
- Revenue This Year
- PLXS $7.81
- OGN $3.11
- Revenue Next Year
- PLXS $10.59
- OGN $2.55
- P/E Ratio
- PLXS $39.67
- OGN $2.89
- Revenue Growth
- PLXS N/A
- OGN 4.21
- 52 Week Low
- PLXS $90.18
- OGN $13.58
- 52 Week High
- PLXS $170.07
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- PLXS 46.81
- OGN 37.20
- Support Level
- PLXS $158.51
- OGN $14.39
- Resistance Level
- PLXS $167.56
- OGN $15.15
- Average True Range (ATR)
- PLXS 3.58
- OGN 0.52
- MACD
- PLXS -1.56
- OGN -0.02
- Stochastic Oscillator
- PLXS 11.70
- OGN 8.63
About PLXS Plexus Corp.
Plexus Corp is a U.S based Electronic Manufacturing Services company that provides a range of services, from conceptualization and design to fulfilling orders and providing sustaining solutions, such as replenishment and refurbishment. The company's segments comprise AMER, APAC,ge and EMEA.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.